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BACKGROUND: The activity of the protein kinase Akt is frequently dysregulated in cancer and is an important factor in the growth and
survival of tumour cells. Akt activation involves the phosphorylation of two residues: threonine 308 (Thr308) in the activation loop
and serine 473 (Ser473) in the C-terminal hydrophobic motif. Phosphorylation of Ser473 has been extensively studied in tumour
samples as a correlate for Akt activity, yet the phosphorylation of Thr308 or of downstream Akt substrates is rarely assessed.
METHODS: The phosphorylation status of Thr308 and Ser473 was compared with that of three separate Akt substrates – PRAS40,
TSC2 and TBC1D4 – in fresh frozen samples of early-stage human non-small cell lung cancer (NSCLC).
RESULTS: Akt Thr308 phosphorylation correlated with the phosphorylation of each Akt substrate tested, whereas Akt Ser473
phosphorylation did not correlate with the phosphorylation of any of the substrates examined.
CONCLUSION: The phosphorylation of Thr308 is a more reliable biomarker for the protein kinase activity of Akt in tumour samples
than Ser473. Any evaluation of the link between Akt phosphorylation or activity in tumour samples and the prediction or prognosis of
disease should, therefore, focus on measuring the phosphorylation of Akt on Thr308 and/or at least one downstream Akt substrate,
rather than Akt Ser473 phosphorylation alone.
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The stimulation of cell growth and survival by numerous growth
factors involves the activation of the phosphoinositide 3-kinase (PI3-
kinase). This leads to the production of phosphoinositide(3,4,5)tris-
phosphate (PI(3,4,5)P3) and the consequent activation of the protein
serine/threonine kinase Akt (also known as protein kinase B). The
activation of Akt involves the phosphorylation of two residues:
threonine 308 (Thr308) in the activation loop of the kinase by the
protein kinase PDK1, and serine 473 (Ser473) in the hydrophobic
motif by the mTORC2 complex (Alessi et al, 1997; Vanhaesebroeck
and Alessi, 2000; Sarbassov et al, 2005). Activated Akt then
phosphorylates numerous downstream substrates, including glyco-
gen synthase kinase-3 (GSK3a/b), tuberous sclerosis complex-2
(TSC2), Foxo-family transcription factors, Bad, Par-4, PRAS40 and
TBC1D4 (Manning and Cantley, 2007). It is these proteins that
together provide potent growth, survival and metabolic signals to the
cell (Hanada et al, 2004; Goswami et al, 2005).
The Akt pathway represents one of the most frequently
dysregulated pathways found in human cancer (Altomare and
Testa, 2005; Cheng et al, 2005) and is a critical mediator of the
survival and proliferative effects of several oncogenes including
mutant forms of the EGF receptor, Ras and PI3-kinase, as well as
the Bcr-Abl fusion protein (Yuan and Cantley, 2008). The activity
of the Akt pathway is counteracted by the PI(3,4,5)P3 phosphatase,
PTEN, and mutations in or haploinsufficiency of PTEN are
frequently observed in human tumours (Li et al, 1998; Cantley
and Neel, 1999; Ramaswamy et al, 1999; Sun et al, 1999).
Because of the importance of the Akt pathway in tumourigen-
esis, Akt activity represents a potential biomarker for use in
disease prognosis or in predicting tumour response to therapeu-
tics. This biomarker may provide an indicator of sensitivity or
resistance to small molecule therapeutics directed at upstream
regulators such as the epidermal growth factor receptor (EGFR) or
PI3-kinase, as well as Akt itself (Pal et al, 2010).
This leads to the question of how best to evaluate Akt activity as a
biomarker. In the vast majority of studies on Akt in cancer, the
measurement of phosphorylation on Ser473 has been used as an
indicator of Akt activity. However, using Ser473 as a measure of Akt
activity often leads to contradictory conclusions regarding whether
Akt activity is prognostic for various cancers. For example, in non-
small cell lung cancer (NSCLC) phosphorylation of Akt on Ser473
has in some studies been found to correlate with poor prognosis
(David et al, 2004; Tang et al, 2006; Lim et al, 2007), whereas others
have found that it has no prognostic significance (Mukohara et al,
2003; Tsao et al, 2003; Massion et al, 2004). Contradictory
observations have also been found in other types of tumour;
phosphorylation on Ser473 has been correlated with poor prognosis
in breast and ovarian cancer (Perez-Tenorio and Stal, 2002; Dai et al,
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s2005) whereas other studies find this not to be the case (Slipicevic
et al, 2005; Al-Bazz et al, 2009). Interpretation of such data is
confounded by whether Akt phosphorylation on Ser473 is a reliable
surrogate for Akt activity, which is ultimately what is important for
the proliferation and survival of the tumour cells.
A more reliable in vivo biomarker of Akt activity may be the
phosphorylation of Thr308, arguably the more important regulator
of Akt activity (Vanhaesebroeck and Alessi, 2000). Although much
more rarely investigated than Ser473 phosphorylation, there are
reports that the phosphorylation of Thr308 correlates with poor
survival in NSCLC (Tsurutani et al, 2006) and acute myeloid
leukaemia (Gallay et al, 2009) and, interestingly, in both reports no
such correlation was seen with Akt Ser473 phosphorylation. This
suggests that the extent of Thr308 phosphorylation may be the
better predictor of Akt activity.
However, the most reliable measure of Akt activity in vivo may
be through the analysis of the phosphorylation of downstream
targets of the kinase along with the phosphorylation of Akt itself.
There are very few studies that have done this.
We wished to carry out such an analysis for NSCLC as it continues
to be a leading cause of cancer death worldwide. In addition, studies
relating Akt activity to clinical outcome in NSCLC are contradictory
possibly because they rely almost solely on the phosphorylation of
Ser473 as a marker. We have therefore undertaken a detailed and
quantitative examination of the activation of Akt in normal and
patient-matched tumour tissue from individuals with NSCLC. Herein
we analyse the phosphorylation of Akt on Ser473 and Thr308 and
correlate this with the activity of the kinase as determined by the
phosphorylation of three well-characterised substrates: PRAS40
(Nascimento and Ouwens, 2009), TSC2 (Cai et al, 2006) and TBC1D4
(Kane et al, 2002).
MATERIALS AND METHODS
Materials
Rabbit polyclonal pAkt (Thr308), pAkt (Ser473), pTBC1D4
(Thr642), pPRAS40 (Thr246) and pTSC (Ser939) antibodies were
purchased from Cell Signalling Technology (Boston, MA, USA).
Mouse anti-F1-ATPase antibody was from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA). Donkey horseradish peroxidase-
conjugated anti-mouse IgG and anti-rabbit IgG antibodies were
purchased from Jackson ImmunoResearch Laboratories (Bar
Harbor, ME, USA).
Patients and tissue samples
Patients with suspected lung cancer were identified from an elective
thoracic surgery list at the Bristol Royal Infirmary, Bristol, UK. A
Research Nurse contacted study subjects regarding participation and
informed consent was given to use their tumour and matched
normal lung tissue. The study was approved by the local research
ethics committee (REC no: 07/Q2002/6, South West 4 REC).
The research nurse was present at thoracic surgery to collect the
tissue, which was surplus to diagnostic requirements. This was
separated into individual samples of tumour and normal tissues,
which were immediately snap frozen in liquid nitrogen. A
pathologist recorded the histology and stage of the tumour, and
made an assessment of the percentage of tumour cells present in
each tumour sample. Only those NSCLC tumour samples comprising
at least 90% of tumour cells were included further in the study. All
samples were stored at  801C until required for analysis.
The cohort had an average age of 64.5 years, 71% were male,
10% were non-smokers, 10% had accumulated 1–10 pack years,
27% 11–30 pack years and 53% 430 pack years (one pack year
being defined as 20 manufactured cigarettes smoked per day for
1 year). Three patients had previously been exposed to asbestos.
Following surgery, all tumours were confirmed to be stage I/IIa
and histology showed that 53% were adenocarcinomas, 40%
squamous cell carcinomas and 3% bronchiolalveloar carcinomas.
Preparation of tissue lysates
Frozen tissue samples were homogenised using a Polytron homo-
geniser in 3ml ice-cold extraction buffer (50mM Tris pH 7.5, 120mM
NaCl, 1% (v/v) Nonidet-P40, 40mM b-glycerophosphate, 1mM
benzamidine, 1mM EDTA, 50mM NaF, 10mM Na4P2O7,1 0 mgml
–1
pepstatin, 10mgml
–1 antipain, 10mgml
–1 leupeptin, 5mM Na3VO4
and 2mM phenylmethylsulphonyl fluoride). Samples were pulsed for
10s followed by a 30-s incubation on ice; a procedure repeated three
times. Tissue lysates were rotated end-over-end at 41Cf o r3 0 m i n ,
and rested on ice for 15min before centrifugation at 16000g for
15min to remove insoluble material. Protein concentration was
determined by BCA assay (Thermo Scientific, Rockford, IL, USA).
Tissue lysates were stored at  801C.
Western blot analysis
Lysates (15mg protein) were solubilised by boiling in 4  Laemmli
sample buffer and separated by SDS–PAGE using 4-12% gradient
gels (Invitrogen Ltd, Paisley, UK). Proteins were transferred to
polyvinylidene difluoride membranes (Millipore, Hertfordshire,
UK). Membranes were blocked using 5% (w/v) bovine serum
albumin in TBS-T (20mM Tris pH 7.4, 137mM NaCl, 0.1% (v/v)
Tween-20) for 1h, washed five times in TBS-T and then incubated
with primary antibody (1mgml
–1) for 1h in TBS-T containing 5%
w/v bovine serum albumin. The membranes were again washed
five times in TBS-T and then incubated with the appropriate
secondary antibodies diluted in TBS-T for 1h. Immunoblots were
visualised using the enhanced chemiluminescence (ECL) detection
system (Amersham Biosciences, Amersham, UK).
Data and statistical analysis
Three separate samples of tumour tissue and three separate samples
of normal tissue from an individual patient were subjected to
western blotting and ECL detection. Normal and tumour protein
samples from individual patients were separated on different gels
and therefore the absolute levels of phosphorylation between
patients were not compared. The extent of phosphorylation of each
protein was quantified by densitometric scanning of the western
blot (Quantity One Software, Bio-Rad, Hemel Hempstead, UK). Data
are expressed as mean±s.e.m., and the strength of evidence for the
difference in phosphorylation between the normal and tumour
samples was determined by Kruskal–Wallis rank order test
(Po0.05). Changes in phosphorylation in tumour samples relative
to normal samples were coded with the values 0 (signifying an
increase observed at Pp0.05), 1 (decrease at Pp0.05) or 2 (no
change, i.e., P40.05) in the tumour tissue relative to normal. The
Spearman’s distribution-free rank correlation test was applied to the
data to test pair-wise correlations between the phosphorylation of
Akt on Thr308 or Ser473 and the phosphorylation of the three Akt
substrates PRAS40, TSC2 and TBC1D4. Quantitatively similar
results were obtained when analysing the data using the Pearson’s
correlation coefficient test (data not shown).
RESULTS
The study cohort comprised 29 patients undergoing thoracic
surgery for suspected lung cancer. Following resection from the
patient, three samples of tumour were snap frozen in liquid
nitrogen. Samples were confirmed by analysis of frozen sections to
consist of at least 90% tumour tissue. Three samples of normal
lung tissue were also taken from the resection margin surrounding
the tumour and snap frozen. The use of patient-matched normal
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stissue allowed us to determine whether protein phosphorylation
was increased, decreased or unchanged in the tumour relative to
normal lung from that particular individual.
Analysis of Akt phosphorylation on Thr308 and Ser473
Three separate samples of tumour and three samples of patient-
matched normal tissue were lysed and subjected to SDS–PAGE
followed by western blotting for the level of phosphorylation of
Akt on Thr308 and Ser473, as well as the phosphorylation of the
well-characterised downstream Akt substrates PRAS40 (on
Thr246), TSC2 (on Ser939) and TBC1D4 (on Thr642).
Figure 1A shows data compiled for the phosphorylation of Akt
on Thr308 in all 29 tumour samples (dark grey bars) compared
with samples of patient-matched normal tissue (light grey bars). In
order to compare the data between patients, the data are
reorganised in Figure 1B according to the magnitude of the fold
change: from highest fold increase to highest fold decrease in
tumour compared with normal tissue. Figure 2A and B shows a
parallel analysis of the phosphorylation of Akt on Ser473.
Akt phosphorylation on Thr308 was increased in 12 out of 29
(41%) of tumours (at Po0.05; Kruskal–Wallis test) when compared
with normal tissue. The magnitude of the change varied, but in four
tumours this was in excess of a ten-fold increase. Akt Thr308
phosphorylation was decreased in 8 out of 29 (28%) of tumours
(Po0.05); again the magnitude varied but in three tumours this was
greater than a ten-fold decrease. In the remaining nine tumours, Akt
Thr308 phosphorylation was apparently unchanged (i.e., P40.05).
A similar analysis of the data for Akt phosphorylation on Ser473
showed that it was increased in 6 out of 29 tumours (21%;
Po0.05), decreased in 14 out of 29 tumours (48%; Po0.05) and
unchanged in the remaining 9 tumours, when compared with
normal tissue.
The frequency of the increased phosphorylation was, therefore,
less for Ser473 phosphorylation than we observed for Thr308,
but conversely the decreases were more frequent. The reasons
for the decreases observed are not known but may be the result of
downregulation of Akt signalling in some tumours.
We next coded the data for Thr308 and Ser473 phosphorylation
according to whether they increased (black) or decreased (grey) at
Po0.05. The coded data are represented within the chart in
Figure 3 and are grouped according to the direction of change in
Thr308 phosphorylation. Of the 12 cases where Thr308 phosphor-
ylation was increased relative to normal tissue (termed group Ia
tumours in Figure 3), Ser473 phosphorylation was increased in
parallel in only 6 cases. In three tumours (designated group Ib),
Ser473 phosphorylation was regulated in a diametrically opposite
manner to Thr308 phosphorylation.
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Figure 1 Phosphorylation of Akt on Thr308 in NSCLC tumour tissue in comparison with patient-matched normal lung tissue. Triplicate samples of lysate
from patient-matched normal (N1–3) and tumour (T1–3) tissues were separated on SDS–PAGE gels. Phosphorylation of Akt on Thr308 was determined
by western blotting with a pAkt-Thr308 antibody followed by quantitation by densitometric scanning. (A) Quantified data for all 29 patients. Each bar
represents the average phosphorylation for normal (N1–3; light grey) or tumour (T1–3; black) tissue for each patient (mean±s.e.m.). The strength of
evidence for a difference in phosphorylation between the normal and tumour samples was determined by Kruskal–Wallis test; *Po0.05. (B) The
percentage change in Akt-Thr308 phosphorylation in tumour samples in comparison with patient-matched normal tissue where patients are ranked in order
of the extent of the percentage change in phosphorylation.
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decreased, Ser473 phosphorylation was decreased in parallel and
these are termed group II tumours. In the nine cases where Thr308
phosphorylation was unchanged (P40.05), Ser473 phosphoryla-
tion was also unchanged in five but was decreased in the remaining
four cases (group III tumours).
To summarise, Akt Thr308 and Ser473 phosphorylation were
regulated in an identical manner (increased, decreased or
unchanged) in just 18 out of the 29 cases studied. Given the
complex interplay between these sites with respect to regulation of
kinase activity, this raised the question of which of Akt Thr308 or
Ser473 phosphorylation correlates best with Akt activity.
Evaluation of the phosphorylation of Akt substrates
When active, Akt phosphorylates numerous downstream sub-
strates that bring about the pleiotropic biological effects of this
kinase. We undertook a detailed examination of the phosphoryla-
tion of three well-characterised Akt substrates in the tumour
samples: PRAS40 (on Thr246), TSC2 (on Ser939) and TBC1D4 (on
Thr642). PRAS40 and TSC2 are both important regulatory
components of the mTOR complex. TBC1D4 is a Rab GTPase-
activating protein that plays a role in the regulation of glucose
metabolism.
The data for the phosphorylation of all three substrates are
provided in Supplementary Figures 1–3, and are summarised in
the chart of Figure 3. Examples of some of the originating western
blot data are provided in Figure 4.
In the nine group Ia tumours, where Akt Thr308 phosphoryla-
tion was increased, the phosphorylation of at least one of the three
Akt substrates was also increased (Figures 3 and 4A) in all except
one patient (patient 18, Figure 3). In all three group Ib tumours,
where Akt Thr308 phosphorylation was increased but Ser473 was
decreased, the phosphorylation of all three Akt substrates was
increased (Figures 3 and 4B), strongly suggesting that Thr308
phosphorylation correlates best with the activity of Akt towards
downstream substrates.
In group II tumours, reduced Akt phosphorylation on Thr308
was accompanied by reduced phosphorylation of at least one of the
three Akt substrates in all except two tumours (patients 14 and 16;
Figures 3 and 4C). Finally, in the nine group III tumours, where
Akt Thr308 phosphorylation was unchanged, the phosphorylation
of all three Akt substrates was also unchanged in six out of nine
patients (Figure 3).
The data in Figure 3 were examined using the Spearman’s rank
correlation test for pair-wise correlation between the phosphorylation
of Akt on Thr308 or Ser473 and the phosphorylation of each of the
substrates. The analysis is summarised in Table 1. This demonstrated
that the phosphorylation of each of the three Akt substrates
correlated with Akt phosphorylation on the activation loop Thr308
(Po0.01 in all three cases) but did not correlate with phosphorylation
of Ser473 in the hydrophobic motif (PX0.05 in each case).
*
%
 
C
h
a
n
g
e
 
i
n
 
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
Patient number
>–1500
–1000
–500
0
500
1000
>1500
Patient number
0
10
20
30
40
50
01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
* *
*
* *
*
*
*
*
*
*
*
*
*
*
*
*
* *
09 24 18 10 03 11 22 13 19 21 28 06
08 02 01 04 27 25 29 17 23 14 05 12 20 07 15 26 16
* *
*
* * *
* * *
*
*
*
*
*
* * * * * *
A
k
t
 
S
4
7
3
 
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
Figure 2 Phosphorylation of Akt on Ser473 in NSCLC tumour tissue in comparison with patient-matched normal lung tissue. Samples were western
blotted and the data quantified exactly as described in Figure 1. (A) The extent of Ser473 phosphorylation in normal (N1–3; light grey) or tumour (T1–3;
black) tissue for each patient (mean±s.e.m.; *Po0.05). (B) The percentage changes in Akt Ser473 phosphorylation in tumour samples in comparison with
patient-matched normal tissue with patients are ranked according to the percentage change in phosphorylation.
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to increase under conditions where the phosphorylation of Akt
and one or both of PRAS40 and TSC2 were unchanged or
decreased. This was most specifically the case for TBC1D4
phosphorylation on Thr642 (hence the lower correlation with
Akt Thr308 phosphorylation compared with PRAS40 and TSC2).
TBC1D4 Thr642 has also been reported to be a substrate for p90
ribosomal S6 kinase 1 and serum- and glucocorticoid-induced
protein kinase 1 (Geraghty et al, 2007), the activity of which may
be elevated in these tumours. This possibility will require future
investigation.
DISCUSSION
In the era of targeted therapy, the assessment of Akt activity in
tumours will move from determining its importance in the genesis of
cancer to establishing its activity in individual tumours as a means of
defining targeted treatment. It is critical that there are methods by
which Akt activity can be reliably determined, in the particular tissue
and pathological condition being examined or treated.
Lung cancer is the leading cause of cancer death worldwide and
NSCLC accounts for 80% of all cases. In NSCLC, Akt activity
represents an attractive and quantifiable biomarker for predictive,
prognostic and pharmacodynamic purposes (Solomon and Pearson,
2009). The majority of studies aimed at evaluating the predictive
power of Akt phosphorylation for patient survival have focussed on
Ser473 rather than Thr308 phosphorylation, probably in large part
because phosphoSer473 antibodies are relatively effective, particu-
larly in immunohistochemical (IHC) analyses. As a consequence, few
studies have analysed Akt phosphorylation on Thr308.
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Figure 3 Examination of the correlation between Akt Thr308 and
Ser473 phosphorylation and the phosphorylation of Akt substrates.
Triplicate samples of normal and patient-matched tumour tissues were
separated on SDS–PAGE gels. Phosphorylation of Akt (on Thr308 and
Ser473) and three downstream substrate proteins (PRAS40-Thr246,
TSC2-Ser939 and TBC1D4-Thr642) was determined by western blotting
with phospho-specific antibodies. The data were quantified by densito-
metry and the strength of evidence of difference in phosphorylation
between the normal and tumour samples was determined by Kruskal–
Wallis test. Phosphorylation of each protein/site was then coded according
to whether it increased (black), decreased (grey) at Pp0.05 or remained
unchanged (white; P40.05) in the tumour samples relative to normal
tissue. The coded data were then grouped according to the direction of
change in Thr308 phosphorylation: patients in group I showed an increase,
group 2 a decrease and group 3 no change. Group I were further
subdivided according to the change in Akt Ser473 phosphorylation (group
Ia showing an increase or no change, and group Ib a decrease).
Group Ia
p-AKT T308
p-TBC1D4 T642
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Normal Tumour
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Normal Tumour
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Normal Tumour
Figure 4 Examples of Akt Thr308 and Ser473 phosphorylation, together
with the phosphorylation of downstream substrates. Triplicate lysates of
normal (N1–3) and patient-matched tumour (T1–3) tissues were
separated on SDS–PAGE gels. Phosphorylation of Akt on Thr308 and
Ser473, and of three downstream substrates, was determined by western
blotting with phospho-specific antibodies as indicated. An anti-F1-ATPase
antibody was used as a control for protein loading. (A) Examples (patients
11 and 24) of tumours in group Ia. (B) Examples of tumours from two
patients (patients 17 and 27) in group Ib. (C) Examples of two patients
(patients 4 and 7) in group II.
Table 1 Correlation between the phosphorylation of Akt on Thr308 or
Ser473 and the phosphorylation of downstream Akt substrates
pPRAS40 pTSC2 pTBC1D4
Akt-pThr308
R 0.752 0.676 0.465
p o0.1 10
–3 o0.1 10
–3 8.3 10
–3
Akt-pSer473
R 0.352 0.229 0.137
p 0.052 0.216 0.462
Abbreviations: Ser473¼serine 473; Thr308¼threonine 308. The table provides the
correlation coefficient (R) and degree of significance (p) obtained for each variable
shown using the Spearman’s pair-wise correlation test.
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much better indicator of the protein kinase activity of Akt in NSCLC
than phosphorylation on Ser473 (Figure 3 and Table 1). We reached
this conclusion through examining the correlation between Akt
phosphorylation on each of Thr308 and Ser473, and the activity of
the Akt kinase as indicated by the state of phosphorylation of three
well-characterised Akt substrates: PRAS40, TSC2 and TBC1D4. The
observation that Akt Thr308 phosphorylation is the better indicator
of activity was most obvious in group Ib tumours in which the
phosphorylation of Akt on Thr308 and all three Akt substrates were
increased, but the phosphorylation of Akt on Ser473 was decreased
(Figures 3 and 4B). However, across all tumours there was a
significant correlation between Thr308 phosphorylation and the
phosphorylation of all three substrates, but no such correlation for
Ser473 phosphorylation.
Our conclusion is consistent with the fact that Thr308 is the major
regulator of Akt kinase activity. For example, phosphorylation of
purified Akt on Thr308 by recombinant active PDK1 increases Akt
protein kinase activity by 30-fold (1, 28, 29), presumably as a result of
a major conformational change in t h ee n z y m et h a ta l l o w ss u b s t r a t e
binding and phosphorylation (Pearce et al, 2010). Independent
phosphorylation of purified Akt on Ser473 in vitro by DNA-
dependent protein kinase (DNA-PK) also activates Akt but only by
approximately ten-fold (Feng et al, 2004). Studies with Akt
phosphorylation site mutants suggest that the phosphorylation of
Thr308 and Ser473 may act in synergy to stimulate Akt activity
(Alessi et al, 1996). However, staurosporine attenuates the activation
of Akt in cultured HEK293 cells stimulated with insulin in parallel
with an inhibition of Thr308 phosphorylation, but has no effect on
Ser473 phosphorylation (Hill et al, 2001). This observation is
consistent with the fact that staurosporine potently inhibits PDK1
(32) but has little effect on mTORC2 (Hresko and Mueckler, 2005),
which is widely agreed to be the physiologically relevant Ser473
kinase in most cell types (Sarbassov et al,2 0 0 5 ) .T a k e nt o g e t h e r ,t h e
data suggest that Ser473 does not play a significant role in regulating
Akt activity in HEK293 cells and our results strongly suggest that
Thr308 phosphorylation is the primary regulator of Akt activity, at
least in NSCLC tumours.
That we demonstrate Thr308 phosphorylation to be a better
marker for Akt activity than Ser473 phosphorylation could help to
explain why Tsurutani et al (2006) found that Thr308 phosphoryla-
tion was a better predictor than Ser473 phosphorylation for poor
overall survival in NSCLC. We propose that this was because these
tumours possess the highest Akt activity, which was responsible for
driving tumour cell proliferation and survival. As Ser473 is
phosphorylated by the mTORC2 complex (and possibly integrin-
linked kinase and DNA-PK in some cell types), measurements of its
phosphorylation may report the activity of the upstream Ser473
kinase(s) rather than activity of Akt itself, and hence care should be
exercised when using this phosphorylation site as a biomarker.
To our knowledge, no studies have assessed Akt activity in
NSCLC by looking at phosphorylation of both Ser473 and Thr308
in addition to substrate phosphorylation. Although when studying
Akt activation in NSCLC, Balsara et al (2004) found that the
phosphorylation of two Akt substrates (mTOR and FKHR) was
significantly associated with the phosphorylation of Akt on Ser473.
There are notable differences in methodology between this study
and ours that may explain the discrepancy in results with respect
to the correlation of Ser473 with substrate phosphorylation. By
rapidly flash freezing tissue samples, the current study was
designed to minimise changes in phosphorylation whereas
Balsara et al (2004) used archival paraffin-embedded samples that
may not have been subject to such handling. Secondly, we obtained
our data by a comparison of phosphorylation in tumour tissue
with that in patient-matched normal tissue rather than correlating
Akt and substrate phosphorylation in individual tumour sections.
A recent study reported that the phosphorylation of PRAS40 on
Thr246 positively correlated with the activation of the PI3-kinase
pathway and predicted an increased sensitivity of tumour cell growth
to an Akt inhibitor in lung and breast cancer cell lines (Andersen
et al, 2010). Taken together with our own data, showing PRAS40 to
strongly correlate with Akt Thr308 phosphorylation, suggests that Akt
Thr308 and/or PRAS40 Thr246 phosphorylation would be good
candidate biomarkers to assess Akt activity in NSCLC.
The data in our current study suggest that the regulation of Akt
activity in NSCLC is complex. Akt activity, as judged by increased
phosphorylation of Akt on Thr308 and at least one downstream
substrate, was elevated in 12 (41%) of the tumours we examined. We
did not examine the upstream defects responsible for the activation of
Akt; however, we did find that EGFR tyrosine phosphorylation was
significantly elevated in 6 of these 12 tumours, suggesting that
changes in EGFR activity might have been responsible (data not
shown). Clearly, however, other mechanisms will also play a role such
as increased activity of the insulin-like growth factor receptor or cMet
and PTEN mutation status.
It is of interest that Akt Thr308 phosphorylation and activity
were reduced in a significant number of tumours (group II;
Figure 3). This may be a result of feedback inhibition of Akt
because of persistent activation of the downstream mTOR
complex, as previously reported (Shah et al, 2004; O’Reilly et al,
2006). Therefore, we propose that this group of tumours would be
unlikely to respond to inhibitors of Akt and PI3-kinase.
Our observations have important consequences for the future
use of Akt as a molecular biomarker in predicting the efficacy of
targeted therapy against the PI3-kinase/Akt pathway and its
regulators. We propose that any evaluation of the link between
Akt phosphorylation in tumour samples and the prediction or
prognosis of disease should focus on the phosphorylation of
Thr308 and/or at least one downstream Akt substrate, rather than
Ser473 phosphorylation alone, in order to more reliably determine
the activity of the kinase and thus better guide disease prognosis
and treatment. Furthermore, although our current results pertain
to NSCLC, they almost certainly have relevance to other tumour
types in which this kinase plays a role in tumourigenesis.
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